Deniz Kent

Deniz Kent is the co-founder and CEO of Prolific Machines Inc. Deniz has a PhD from King's College London, where their research was focused on developing a new therapeutic for patients with alpha-1 antitrypsin deficiency. Deniz also has a Visiting Scholar from the University of Massachusetts Medical School.

Deniz Kent completed their Doctor of Philosophy (Ph.D.) in Stem Cell Biology at King's College London. Deniz also holds a Masters in Biomedical and translational science from King's College London, where they graduated with distinction. Her undergraduate degree is in Cellular and Molecular Medicine from the University of Bristol.

Victor Jones - CSO, Madeleine Allen - Hardware Engineer, and Monique Hooley - Head of Cell Biology report to Deniz Kent.